Boltz raises $110 million to accelerate AI-driven drug discovery
The London-based startup aims to use its new funding to build models that help scientists design new medicines entirely on computers.

The short version
- Boltz raised $110 million in a Series A round led by Bessemer Venture Partners.
- The company employs 40 AI researchers in London to build drug discovery software.
- Boltz has established partnerships with major pharmaceutical companies including Pfizer and GSK.
- The startup offers open-source models while generating revenue through platform access and partnerships.
Why it matters
This investment signals a shift toward using AI to compress the early stages of drug discovery, which is traditionally slow and expensive. If successful, it could allow scientists to move from a hypothesis to a viable molecule much faster.
Securing major investment
Boltz, a startup based in London, recently closed a $110 million Series A funding round. The investment was led by Bessemer Venture Partners and includes participation from several existing and new investors. This funding comes less than a year after the company emerged from stealth mode.
The company is using the capital to scale its operations significantly. Specifically, Boltz plans to spend the funds on expanding its team of researchers and securing more compute and data. These resources are essential for training the complex AI models required to simulate chemical interactions.
The funding round follows a $28 million seed round raised at the beginning of the year. Combined, the company has raised $138 million to date. This influx of capital arrives as the market for AI-driven drug discovery becomes increasingly crowded with new competitors.
From MIT to London
The startup has deep academic roots, having emerged from the Massachusetts Institute of Technology (MIT). The co-founders gained attention there by releasing open-source AI models that performed as well as closed-source systems like DeepMind's AlphaFold3. These models are now being used by researchers as a standard tool for early-stage drug discovery.
Boltz currently operates out of London's King's Cross district, where it employs 40 AI researchers. The team focuses on building software that assists pharmaceutical and biotech researchers in designing potential drugs. Their primary goal is to help these scientists decide which specific candidates are worth testing in physical laboratories.
The company's technology is designed to predict bound structures and estimate binding strength. By proposing new molecules for specific targets, the software helps narrow down the vast number of possibilities in chemistry. This allows researchers to focus their physical experiments on the most promising leads.
How the models work
Boltz develops its technology through its own platform and an API, which allows other developers to integrate its tools. The company provides both open-source AI models and proprietary models for various uses. This dual approach allows them to build a community of users while maintaining a path to commercial revenue.
The core of their technology involves predicting how molecules will interact with biological targets. These AI models can estimate the strength of those bonds, which is a critical factor in determining if a drug will be effective. By simulating these interactions digitally, the company aims to reduce the time spent on trial and error in a lab.
The company's long-term vision is to create a world where a scientist can move from a therapeutic hypothesis to a human-ready molecule without leaving their computer. To reach this goal, Boltz believes it must continue to make substantial advances in model quality and data processing capabilities.
Pharma partnerships
Boltz is already integrating its technology into the workflows of some of the world's largest pharmaceutical companies. The startup has announced collaborations with major industry players including Pfizer, GSK, Takeda, and Bristol Myers Squibb. These partnerships are a key part of the company's business model and growth strategy.
The company generates revenue through these high-level partnerships and by selling access to its platform and models. This creates a balance between providing open-source tools to the broader scientific community and offering premium services to large corporations. This model helps Boltz navigate the tension between open science and commercial viability.
While the company did not disclose specific revenue figures or its current valuation, the involvement of major pharma brands suggests significant industry trust. These partners rely on Boltz to help compress the early discovery work that typically takes years and costs millions of dollars.
The road ahead
Despite the progress in software predictions, drug discovery remains a capital-intensive process that requires physical testing. Boltz must prove that its AI predictions hold up when they are eventually tested in real-world experiments. The success of the company depends on the accuracy of these digital simulations in a biological context.
The company is currently working on upcoming models that are already showing improvements in the quality of the molecules they generate. Boltz intends to use its new funding to push these models toward an exponential trajectory of capability. They are aiming to make their tools the default choice for the next generation of drug design.
As the AI drug discovery market grows, Boltz faces the challenge of staying ahead of competitors who are also raising large rounds. By focusing on both open-source contributions and deep pharmaceutical integrations, the company hopes to establish itself as a foundational layer for the future of medicine.
What to watch
- Whether Boltz's predicted molecules successfully pass physical lab testing in their partner programs.
- How many more major pharmaceutical companies sign on to the Boltz platform this year.
Try it
Look up the open-source models released by Boltz's co-founders at MIT to see how they compare to AlphaFold3.
Sources and links
- Reportingnews.lavx.hu: the article we sourced
First reported by news.lavx.hu. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.